Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Abstract

Jingjing Li, Xuanfu Xu Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of ChinaCorrespondence: Xuanfu Xu, Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of China, Tel [phone], Email [email protected]: Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body’s autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.Keywords: immune checkpoint inhibitors, colorectal cancer, PD-1/PD-L1, combination therapy, DNA mismatch repair

Keywords

• immune checkpoint inhibitors
• colorectal cancer
• pd-1/pd-l1
• combination therapy
• dna mismatch repair